PRPH (ProPhase Labs) Other Current Liabilities: $3.22 Mil (As of Mar. 2026)


What is ProPhase Labs Other Current Liabilities?

ProPhase Labs PRPH -13.60% Other Current Liabilities is $3.22 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

ProPhase Labs's other current liabilities for the quarter that ended in Mar. 2026 was $3.22 Mil.

ProPhase Labs's quarterly other current liabilities declined from Sep. 2025 ($4.90 Mil) to Dec. 2025 ($0.05 Mil) but then increased from Dec. 2025 ($0.05 Mil) to Mar. 2026 ($3.22 Mil).

ProPhase Labs's annual other current liabilities increased from Dec. 2023 ($1.87 Mil) to Dec. 2024 ($5.87 Mil) but then declined from Dec. 2024 ($5.87 Mil) to Dec. 2025 ($0.05 Mil).

ProPhase Labs Other Current Liabilities Related Terms

ProPhase Labs Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for ProPhase Labs's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProPhase Labs Other Current Liabilities Chart

ProPhase Labs Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.05 1.87 5.87 0.05

ProPhase Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.66 2.04 4.90 0.05 3.22

ProPhase Labs Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $3.22 Mil mean?
ProPhase Labs (PRPH) has a Other Current Liabilities of $3.22 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on ProPhase Labs.
Is ProPhase Labs' Other Current Liabilities too high?
ProPhase Labs' current Other Current Liabilities is $3.22 Mil.
How does ProPhase Labs' Other Current Liabilities compare to IDTA and IVRO?
ProPhase Labs' Other Current Liabilities of $3.22 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Diagnostics & Research company?
A good Other Current Liabilities depends on the Medical Diagnostics & Research industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on ProPhase Labs. ProPhase Labs's current Other Current Liabilities is $3.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.08 — trading 87.8% below its estimated fair value. The current Other Current Liabilities is $3.22 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Other Current Liabilities is $3.22 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProPhase Labs Business Description

Address 626 RXR Plaza, 6th Floor, Uniondale, NY, USA, 11556
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.